Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chengde Wu

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Medicinal Chemistry|April 2, 2004
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonistChengde Wu, E Radford Decker, Natalie Blok, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases InhibitorsDonghui Qin, Xiaojuan Lin, Zhi Liu, et al.
ACS Medicinal Chemistry Letters|March 16, 2018
Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTORTao Yu, Ning Li, Chengde Wu, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBSHilary Schenck Eidam, John Russell, Kaushik Raha, et al.
ACS Medicinal Chemistry Letters|October 16, 2020
Discovery and Evaluation of Pyrazolo[3,4-<i>d</i>]pyridazinone as a Potent and Orally Active Irreversible BTK InhibitorXuejun Zhang, Xijun Sheng, Jie Shen, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Medicinal Chemistry|April 2, 2004
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonistChengde Wu, E Radford Decker, Natalie Blok, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases InhibitorsDonghui Qin, Xiaojuan Lin, Zhi Liu, et al.
ACS Medicinal Chemistry Letters|March 16, 2018
Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTORTao Yu, Ning Li, Chengde Wu, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBSHilary Schenck Eidam, John Russell, Kaushik Raha, et al.
ACS Medicinal Chemistry Letters|October 16, 2020
Discovery and Evaluation of Pyrazolo[3,4-<i>d</i>]pyridazinone as a Potent and Orally Active Irreversible BTK InhibitorXuejun Zhang, Xijun Sheng, Jie Shen, et al.
Pageof 2